What could be hotter than Moderna getting in the Claudin18.2 race? How about pairing up a newly disclosed mRNA therapeutic cancer vaccine with a solid-tumor-targeting CAR-T?

什么可能比Moderna进入Claudin18.2比赛更热？如何将新公开的mRNA治疗性癌症疫苗与靶向CAR-T的实体瘤配对？

That sounds like the plan, according to CARsgen Therapeutics. The Chinese biotech is developing CT041, also known as satricabtagene autoleucel, as a Claudin18.2-focused CAR-T for the potential treatment of gastric, pancreatic and other digestive system cancers. Despite being an autologous—as opposed to an allogeneic or “off-the-shelf” therapy—the Shanghai-based company claims that CT041 is the “most advanced solid tumor CAR-T in development” on account of it having entered a “pivotal” phase 2 trial..

根据CARsgen Therapeutics的说法，这听起来像计划。中国生物技术公司正在开发CT041，也称为satricabtagene autoleucel，作为Claudin18.2聚焦的CAR-T，用于治疗胃癌，胰腺癌和其他消化系统癌症。尽管CT041是一种自体疗法，而不是同种异体疗法或“现成的”疗法，但总部位于上海的公司声称CT041是“正在开发的最先进的实体肿瘤CAR-T”，因为它已进入“关键”2期试验。。

The biotech said it has initiated a collaboration agreement with Moderna for the two companies to “contemplate conducting preclinical studies and a phase 1 clinical trial to evaluate CT041 in combination with Moderna’s Claudin18.2 mRNA cancer vaccine.”

该生物技术公司表示，已启动与Moderna的合作协议，让两家公司“考虑进行临床前研究和1期临床试验，以评估CT041与Moderna的Claudin18.2 mRNA癌症疫苗的组合”

Claudin18.2 is a hot cancer target, with Amgen, Astellas and Legend Biotech having thrown a wide spectrum of biologic modalities at it in the belief targeting the tight junction molecule can tackle tumors in the gastrointestinal tract. AstraZeneca has also doubled down on Claudin18.2 this year, paying KYM Biosciences $63 million upfront for the global rights to an early-phase antibody-drug conjugate 10 months after handing over $25 million to Harbour BioMed for a CLDN18.2xCD3 bispecific antibody aimed at the same target..

Claudin18.2是一个热门的癌症靶点，Amgen，Astellas和Legend Biotech已经投入了广泛的生物学模式，因为相信靶向紧密连接分子可以解决胃肠道肿瘤。阿斯利康今年的Claudin18.2也翻了一番，在支付超过2500万美元用于CLDN18.2xCD3双特异性抗体的BioMed港口后10个月，支付KYM Biosciences 6300万美元的全球早期抗体-药物偶联物权利。同一目标。。

When it comes to mRNA therapies, Moderna won’t be the first player in the Claudin18.2 space. BioNTech already has a Claudin18.2 inhibitor called BNT-141 in a phase 1/2 trial for gastric, pancreatic, ovarian and biliary tract tumors.

在mRNA治疗方面，Moderna不会成为Claudin18.2领域的第一个参与者。BioNTech在胃，胰腺，卵巢和胆道肿瘤的1/2期临床试验中已经有一种名为BNT-141的Claudin18.2抑制剂。

“Claudin18.2 is a promising therapeutic target to potentially treat multiple cancer types with high unmet medical need,” Moderna’s chief scientific officer of external research ventures Lin Guey, Ph.D., said in this morning’s release.

Moderna的外部研究企业首席科学官Lin Guey博士在今天早上的发布中说：“Claudin18.2是一种很有前途的治疗靶点，可以潜在地治疗多种癌症类型，并且具有很高的未满足的医疗需求。”。

“We are pleased to partner with CARsgen to explore the potential synergy of CAR-T with an investigational mRNA cancer vaccine that encodes for the Claudin18.2 protein,” Guey added.

“我们很高兴与CARsgen合作，探索CAR-T与编码Claudin18.2蛋白的研究性mRNA癌症疫苗的潜在协同作用，”Guey补充说。

Combining Moderna’s “off the shelf” cancer vaccine with a CAR-T therapy “could potentially provide greater clinical benefit to patients” with tumors, CARsgen CEO and Chief Scientific Officer Zonghai Li, M.D., Ph.D., said in the same release.

CARsgen首席执行官兼首席科学官Zonghai Li博士在同一版本中说，将Moderna的“现成”癌症疫苗与CAR-T疗法相结合可能为患有肿瘤的患者提供更大的临床益处。

Last month, Moderna stirred up interest in another cancer vaccine combo trial when it unveiled details for how it would test a Merck-partnered personalized cancer vaccine with Keytruda in a phase 3 trial for post-surgery treatment of patients with resected melanoma. If eventually successful, Merck and Moderna could open up an entirely new area of cancer treatment..

上个月，Moderna激发了对另一项癌症疫苗组合试验的兴趣，当时它公布了如何在Keytruda的默克合作个性化癌症疫苗进行3期试验的细节，用于手术后治疗切除的黑色素瘤患者。如果最终成功，默克和Moderna可以开辟一个全新的癌症治疗领域。。